tiprankstipranks
Advertisement
Advertisement

CH:BIOV Stock Latest News

BioVersys Wins FDA Fast Track for Lead Antibiotic BV100
Company AnnouncementsBioVersys Wins FDA Fast Track for Lead Antibiotic BV100
7h ago
BIOV
BioVersys schedules half-year results and investor update as late-stage antibacterial pipeline advances
PremiumCompany Announcements
BioVersys schedules half-year results and investor update as late-stage antibacterial pipeline advances
7d ago
BIOV
BioVersys Sets September 9 Date for Half-Year 2026 Results and Strategic Update
PremiumCompany Announcements
BioVersys Sets September 9 Date for Half-Year 2026 Results and Strategic Update
8d ago
BIOV
BioVersys Shareholders Back All Board Proposals, Strengthen Governance at AGM
PremiumCompany Announcements
BioVersys Shareholders Back All Board Proposals, Strengthen Governance at AGM
4M ago
BIOV
BioVersys clears China Phase 1 hurdle for BV100, advancing global pneumonia trial
PremiumCompany Announcements
BioVersys clears China Phase 1 hurdle for BV100, advancing global pneumonia trial
4M ago
BIOV
Buy Rating on BioVersys Driven by Differentiated BV100 and De‑Risked Late‑Stage Development Path to 2028 Regulatory Filings
PremiumRatingsBuy Rating on BioVersys Driven by Differentiated BV100 and De‑Risked Late‑Stage Development Path to 2028 Regulatory Filings
5M ago
BioVersys launches pivotal Phase 3 trial of BV100 for drug-resistant hospital pneumonia
Premium
Company Announcements
BioVersys launches pivotal Phase 3 trial of BV100 for drug-resistant hospital pneumonia
5M ago
BIOV
BioVersys highlights BV100 and BV500 antimicrobial data at ESCMID Global 2026
Premium
Company Announcements
BioVersys highlights BV100 and BV500 antimicrobial data at ESCMID Global 2026
5M ago
BIOV
BioVersys: Strategic Hackensack Partnership and Pivotal BV100 Phase 3 Underpin Buy Rating and CHF40 Target
PremiumRatings
BioVersys: Strategic Hackensack Partnership and Pivotal BV100 Phase 3 Underpin Buy Rating and CHF40 Target
5M ago
BioVersys advances TB portfolio as Nature Communications paper underscores AlpE’s resistance‑breaking potential
PremiumCompany Announcements
BioVersys advances TB portfolio as Nature Communications paper underscores AlpE’s resistance‑breaking potential
5M ago
BIOV
BioVersys Calls 2026 AGM and Proposes Board Refresh as Late-Stage Pipeline Advances
PremiumCompany Announcements
BioVersys Calls 2026 AGM and Proposes Board Refresh as Late-Stage Pipeline Advances
5M ago
BIOV
BioVersys Strengthens Investor Outreach With New IR and Communications Head
PremiumCompany Announcements
BioVersys Strengthens Investor Outreach With New IR and Communications Head
5M ago
BIOV
BioVersys AG: Expanding NTM Ansamycin Platform via HMH Partnership Supports Long‑Term Growth and Reiterated Buy Rating
PremiumRatingsBioVersys AG: Expanding NTM Ansamycin Platform via HMH Partnership Supports Long‑Term Growth and Reiterated Buy Rating
5M ago
BioVersys bolsters anti-NTM pipeline with Hackensack Meridian Health ansamycin deal
Premium
Company Announcements
BioVersys bolsters anti-NTM pipeline with Hackensack Meridian Health ansamycin deal
5M ago
BIOV
BioVersys boosts antibiotic pipeline and cash runway with Phase 3 launch and IPO war chest
Premium
Company Announcements
BioVersys boosts antibiotic pipeline and cash runway with Phase 3 launch and IPO war chest
6M ago
BIOV
BioVersys AG: FDA-Cleared Phase 3 BV100 Program De‑Risks Path to Approval and Supports Buy Rating
PremiumRatings
BioVersys AG: FDA-Cleared Phase 3 BV100 Program De‑Risks Path to Approval and Supports Buy Rating
6M ago
BioVersys Wins FDA Go-Ahead for Global Phase 3 Pneumonia Trial of BV100
PremiumCompany Announcements
BioVersys Wins FDA Go-Ahead for Global Phase 3 Pneumonia Trial of BV100
6M ago
BIOV
BioVersys: Advancing Late‑Stage Infectious Disease Pipeline Drives Buy Rating Ahead of 2027 Catalysts
PremiumRatings
BioVersys: Advancing Late‑Stage Infectious Disease Pipeline Drives Buy Rating Ahead of 2027 Catalysts
6M ago
BioVersys Advances AlpE TB Candidate Into Phase 2b Trial Within UNITE4TB Platform
PremiumCompany Announcements
BioVersys Advances AlpE TB Candidate Into Phase 2b Trial Within UNITE4TB Platform
6M ago
BIOV
BioVersys Sets Date for 2025 Results as Late‑Stage Antibacterial Pipeline Advances
PremiumCompany AnnouncementsBioVersys Sets Date for 2025 Results as Late‑Stage Antibacterial Pipeline Advances
6M ago
BIOV
BioVersys Advances BV100 Antibiotic as Phase 1 Data Published and Global Pivotal Trial Starts
Premium
Company Announcements
BioVersys Advances BV100 Antibiotic as Phase 1 Data Published and Global Pivotal Trial Starts
6M ago
BIOV
BioVersys Advances AlpE Combo Into Phase 2a for Severe Tuberculosis Meningitis
Premium
Company Announcements
BioVersys Advances AlpE Combo Into Phase 2a for Severe Tuberculosis Meningitis
6M ago
BIOV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >